Anteris Technologies Global Corp. specializes in the development of cardiovascular devices, primarily targeting the treatment of heart valve diseases. The company's flagship product is the DurAVR Transcatheter Heart Valve (THV) system, a biomimetic, single-piece valve designed to replicate the natural performance of a healthy human aortic valve. This device is constructed using the company's patented ADAPT tissue technology, an anti-calcification treatment that transforms xenograft tissue into durable bioscaffolds. In addition to the valve, Anteris has developed the ComASUR delivery system, a balloon-expandable catheter designed for precise anatomical navigation and deployment. While originally founded in Australia, the company maintains a significant operational footprint in Minneapolis, Minnesota, to access the U.S. medical technology market and conduct clinical trials. Anteris operates in a highly competitive structural heart market, positioning its products as durable, minimally invasive alternatives to existing transcatheter aortic valve replacement (TAVR) devices.
